The calculator in question is the IMDC Risk Model, also known as the International Metastatic Renal Cell Carcinoma Database Consortium Model. This scoring system is specifically designed for patients with metastatic renal cell carcinoma (mRCC).
The IMDC Risk Model is used to stratify patients into different risk groups (favorable, intermediate, and poor) based on six clinical and laboratory factors. These factors include time from diagnosis to treatment, Karnofsky performance status, hemoglobin, corrected calcium, neutrophils, and platelets.
The clinical utility of this calculator is to predict overall survival and progression-free survival in patients with mRCC. It helps clinicians to make informed decisions about the most appropriate treatment strategy for individual patients, including the selection of first-line targeted therapy and the consideration for clinical trial enrollment.
There are no specific exclusion criteria for the use of the IMDC Risk Model. However, it should be noted that this model may not be applicable or accurate in patients with non-clear cell renal cell carcinoma or in those with brain metastases, as these patients were underrepresented in the original IMDC cohort.
Reference
Daniel Y C Heng, Wanling Xie, Meredith M Regan et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009 Dec 1;27(34):5794-9.
Open reference URL